IXALTIS announced results from the company’s phase 2 program clinical program evaluating litoxetine (LTX) for the treatment of urinary incontinence. Based on the positive results to date, Ixaltis is preparing for meeting with regulatory authorities and finalize plans for phase 3, while also seeking partnership opportunities for pursuing future development. The phase 2 program was comprised of two studies conducted in Europe, Canada and the USA in a total of about 300 patients. Data demonstrated a clinically meaningful treatment effect to reduce involuntary urinary leaks. The effect appeared to be more pronounced in patients with more severe urinary incontinence. The improvement in incontinence frequency (reduction in the number of leaks) is accompanied by an improvement in patient perception of their bladder condition and its impact on their quality of life. LTX was well tolerated, with only a small number of subjects discontinuing treatment due to side effects. Side effects were generally mild or moderate in severity, transient and resolved spontaneously.